Traws Pharma
TRAW
30 hedge funds and large institutions have $3.61M invested in Traws Pharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
300% more call options, than puts
Call options by funds: $32K | Put options by funds: $8K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.09% less ownership
Funds ownership: 0.46% → 0.38% (-0.09%)
12% less funds holding
Funds holding: 34 → 30 (-4)
41% less capital invested
Capital invested by funds: $6.14M → $3.61M (-$2.53M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$349K |
| 2 |
Two Sigma Advisers
New York
|
+$106K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$50.8K |
| 4 |
Millennium Management
New York
|
+$19.6K |
| 5 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$673K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$370K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$232K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$147K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
26
GSA Capital Partners
London,
United Kingdom
| – | -$147K | -2,312 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$104K | -1,625 | Closed |
|
|
JF
28
Jump Financial
Chicago,
Illinois
| – | -$59K | -927 | Closed |
|
|
VF
29
Virtu Financial
New York
| – | -$31K | -481 | Closed |
|
30
Rockefeller Capital Management
New York
| – | -$1K | -16 | Closed |
|
|
HFS
31
Hantz Financial Services
Southfield,
Michigan
| – | +$93 | +2 | New |
|
TRAW Hedge Fund Activity: Q1 2022 in Review
30 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2022, worth a combined $3.61M — down 41% from $6.14M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRAW and 3 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $349K. The largest seller was Vanguard Group, cutting an estimated $673K.
- 30 institutional investors held Traws Pharma (TRAW) as of Q1 2022, down from 34 in Q4 2021.
- Funds reported $3.61M of Traws Pharma stock for Q1 2022, down 41% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest Traws Pharma buyer in Q1 2022 was Renaissance Technologies, an estimated $349K added.
- The largest Traws Pharma seller in Q1 2022 was Vanguard Group, an estimated $673K sold.
Based on aggregated 13F filings for Q1 2022.